VALIANTORGNSE30 May 2025

Valiant Organics Limited has informed the Exchange about Investor Presentation

Valiant Organics Limited

May 30, 2025

To, Listing / Compliance Department BSE LTD Phiroze Jeejeebhoy Towers Dalal Street Mumbai- 400 001 SCRIP CODE – 540145

Dear Sir / Madam,

To, Listing / Compliance Department National Stock Exchange of India Limited Exchange Plaza, Plot No. C/1, G Block Bandra-Kurla Complex, Bandra (E), Mumbai- 400 051. SYMBOL- VALIANTORG

Sub: Investors Presentation

Pursuant to Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, please find enclosed herewith Investors’ Presentation for Q4 FY25 Results of Valiant Organics Limited (the “Company”).

A copy of aforesaid www.valiantorganics.com.

Investor Presentation

is also hosted on

the website of Company

Please take the same on your records.

Thanking you,

Yours faithfully,

For Valiant Organics Limited

Kaustubh Kulkarni Company Secretary ICSI M. No.: A52980

Regd. Office:109, Udyog Kshetra, 1st Floor, Mulund Goregaon Link Rd, Mulund West, Mumbai 400080, India.

+91 22 6797 6683 • info@valiantorganics.com • www.valiantorganics.com

CIN NO.: L24230MH2005PLC151348

E a r n i n g s P r e s e n t a t i o n | Q 4 - F Y 2 5 / F Y 2 5

SNAPSHOT

One of the largest chlorophenol derivatives manufacturer globally

One of the leading manufacturer of Benzene derivatives products

One of the largest domestic PNA manufacturer

One of the few commercial players in Ortho Anisidine and Para Anisidine

Amongst 1st few domestic PAP Manufacturers

Diversified client base across Pharmaceuticals, Dyes & Pigments, Agrochemicals and specialty chemicals.

6 Manufacturing units across 5 Locations

5 Zero Liquid Discharge plants

Total Production Capacity of 70,000 TPA

900+ Employees

Company Overview

Valiant Organics Limited was incorporated in 1984 by first generation technocrats and is headquartered out of Mumbai, India.

The company is focused on the manufacturing and marketing of specialty chemicals which find usage in a variety of industries, including agrochemicals, pharmaceuticals, dyes, pigments, and veterinary medications.

Key chemistries include Chlorination, Hydrogenation, Ammonolysis, Acetylation, Sulphonation, Methoxylation amongst others.

Over the years the company has primarily focused on manufacturing specialty chemicals that have a high demand but low supply and are primarily dependent on imports.

The company is listed on both the BSE and NSE with a market capitalization of INR ~ 7,300 Mn. as on 31st March, 2025.

Operating Revenue (INR Mn) and EBITDA Margin (%)

FY25 Revenue Break-up – Chemistries

FY25 Revenue Break-up – End user Industry

11,533

10,518

17.77%

15.62%

14000

12000

10000

8000

6000

4000

2000

7,231

5.28%

FY22

FY23 Revenue

FY24

EBITDA Margin

50.00%

45.00%

40.00%

35.00%

30.00%

25.00%

20.00%

15.00%

10.00%

5.00%

0.00%

7,188

7.47%

FY25

Others, 5%

Chlorination, 20%

Ammonolysis, 28%

Hydrogenation, 47%

Dyes & Pigments; 52%

Pharmaceuticals; 13%

Specialty Chemicals; 10%

Agro Chemicals; 25%

*Pursuant to the allotment of further equity shares through IPO by the Company's material step down subsidiary namely, Valiant Laboratories Limited ("VLL"), the stake of Company's subsidiary Dhanvallabh Ventures LLP in VLL has been diluted to 46.83% and accordingly VLL has ceased to be a step down subsidiary of the Company and has became an associate company w.e.f. October 04,2023. Hence, consolidated financial of previous periods and YTD results are not comparable.

Valiant Organics Limited | Q4-2025

Chemistries And Product Basket

Ammonolysis

Key Products: • •

Para Nitro Aniline Ortho Chloro Para Nitro Aniline

Industries Served: • •

Dyes Pigments

FY25 Revenue Share

47%

28%

Hydrogenation

Ortho Anisidine Para Anisidine IPPCA

Key Products: • • • • Meta Chloro Aniline • Para Amino Phenol • Ortho Amino Phenol

Industries Served: • • • •

Dyes Pigments Pharmaceutical Agro Chemicals

Others Acetylation Key Products: • • •

6 Acetyl OAPSA OA Acetanilide PA Acetanilide

Industries Served: • Dyes

Sulphonation Key Products: • OT5SA • 4B Acid • 2B Acid

Methoxylation Key Products: • •

Ortho Nitro Anisole Para Nitro Anisole

Industries Served: • Dyes • Pigments

20%

Chlorination

Key Products: • • • • •

Para ChloroPhenol (PCP) Ortho ChloroPhenol (OCP) 2,4 Di Chlorophenol (2,4 DCP) 2,6 Di ChloroPhenol (2,6 DCP) 2,4,6 Tri ChloroPhenol (2,4,6 TCP)

Industries Served: • Agro Chemicals • Cosmetics • Veterinary • Pharmaceuticals

Valiant Organics Limited | Q4-2025

Manufacturing Footprint

CHLORINATION – SARIGAM • Capacity: 18,000 MTPA • Products: PCP, OCP, 2,4 DCP, 2,6 DCP, 2,4,6 TCP

AMMONOLYSIS - VAPI • •

Capacity: 9,000 MTPA Products: PNA, OCPNA

AMMONOLYSIS - TARAPUR • Capacity: 6,600 MTPA • Products: PNA

HYDROGENATION & METHOXYLATION- JHAGADIA UNIT 1 • •

Capacity: 27,000 MTPA Products: ONA/OA, PNA/PA, IPPCA, CONVERSION PRODUCTS

HYDROGENATION – JHAGADIA UNIT 2 • •

Capacity: 12,000 MTPA Products: PAP, PHARMA INTERMEDIATES

ACETYLATION & SULPHONATION – AHMEDABAD • •

Capacity: 1,800 MTPA Products: 6 ACETYL OAPSA, OA/PA ACETANILIDE, OT5SA

Valiant Organics Limited | Q4-2025

Key Strengths

Domain expertise and broad process understanding in a variety of chemistries. The executive team is made up of first-generation technocrats with more than 50 years of collective expertise.

Wide supply chain provides the continuous availability of adequate and high-quality raw materials and manufacturing.

Plant locations are strategically located near ports to provide a competitive advantage, significant logistical cost savings, and faster delivery times.

Robust Business Model

Integrated Operations

Strong Customer Relations

Distinct Product Portfolio

Domain Knowledge

Widespread Supply Chain

Strategic Location of Plants

Diverse product range and client base across numerous industries and countries provides a sustainable business model in multiple chemistries by lowering product, industry, and geographical risk.

Multi-use and backward integrated plants to produce a wide range of products and tailor them to meet the diverse needs, technical qualifications, batch sizes, and delivery schedules of our clients.

Established multi-year relationships with clients in both domestic and international markets due to high-quality standards, innovative production capabilities.

Manufacturing a diverse range of intermediates as well as value-added products for a variety of industries.

Valiant Organics Limited | Q4-2025

Q4-FY25 /FY25 HIGHLIGHTS

Valiant Organics Limited | Q4-2025

CONSOLIDATED FINANCIAL HIGHLIGHTS

Q4-FY25 CONSOLIDATED FINANCIAL HIGHLIGHTS

FY25 CONSOLIDATED FINANCIAL HIGHLIGHTS

INR 203 Mn Operating EBITDA

INR 42 Mn Profit After Tax

INR 1.52/ Share EPS

INR 2,038 Mn Operational Revenue

9.96 % Operating EBITDA Margin

2.06 % PAT Margin

INR 537 Mn Operating EBITDA

INR (34) Mn Profit After Tax

INR (1.24)/ Share EPS

INR 7,188 Mn Operational Revenue

7.47 % Operating EBITDA Margin

(0.47) % PAT Margin

Valiant Organics Limited | Q4-2025

Q4-FY25/FY25 Operational Highlights

• The company reported INR 2,038 millions in revenue for Q4 FY25, reflecting a 15% year on year growth. This performance was driven by higher volumes and improved realizations across key product segments.

Q4-FY25 Revenue Break-up – Chemistries

Others, 2%

• Gross Profit for Q4 FY25 stood at INR 721 millions, with a margin of 35%, marking a significant improvement from 26% in Q4 FY24. For the full year FY25, the Gross Profit Margin expanded to 37%, up from 33% in FY24, driven by a favorable product mix, effective cost optimization measures, and enhanced operational efficiencies.

• EBITDA margins expanded meaningfully due to better operating leverage and

disciplined cost control.

Chlorination, 20%

Ammonolysis, 22%

Hydrogenation, 55%

• Profitability returned in the latter half of the year, reflecting a positive shift in

FY25 Volume Break-up – Chemistries

overall performance.

• Maintained focused execution throughout the year with measurable progress on

strategic priorities.

• Delivered improvements in margin, efficiency, and portfolio rationalization.

• Strengthened the foundation for continued operational resilience.

Others, 2%

Chlorination, 26%

Ammonolysis, 26%

Hydrogenation, 45%

Valiant Organics Limited | Q4-2025

Key Chemistries

Chlorination (INR Mn)

Hydrogenation (INR Mn)

Ammonolysis (INR Mn)

Others (INR Mn)

1,126

879

668

379

380

413

1200

1000

800

600

400

200

Q4-FY24

Q3-FY25

Q4-FY25

Q4-FY24

Q3-FY25

Q4-FY25

2,597

2,786

3,356

3,982

4,430

5,116

6,000

5,000

4,000

3,000

2,000

1,000

582

513

458

Q4-FY24

Q3-FY25

Q4-FY25

3,251

2,764

2,838

700

600

500

400

300

200

100

3,300

3,200

3,100

3,000

2,900

2,800

2,700

2,600

2,500

Q4-FY24

Q3-FY25

Q4-FY25

365

225

108

120

100

400

350

300

250

200

150

100

Q4-FY24

Q3-FY25

Q4-FY25

Q4-FY24

Q3-FY25

Q4-FY25

Q4-FY24

Q3-FY25

Q4-FY25

Q4-FY24

Q3-FY25

Q4-FY25

S E U N E V E R

420

410

400

390

380

370

360

4,000

3,500

3,000

2,500

2,000

1,500

1,000

500

) T M

( S E M U L O V S E L A S

Valiant Organics Limited | Q4-2025

Quarterly Consolidated Financial Performance

Particulars (INR Mn)

Revenue from Operations

Total Expenses

EBITDA

EBITDA Margins (%)

Other Income

Depreciation

Finance Cost

PBT (Excl. Exceptional Items)

Exceptional Items

Share of Profit/(Loss) of Associates

PBT

Tax

PAT

PAT Margins (%)

Other Comprehensive Income

Total Comprehensive Income

Basic/Diluted EPS (INR)

Valiant Organics Limited | Q4-2025

Q4-FY25

Q4-FY24

2,038

1,835

203

9.96%

1,768

1,786

(18)

(1.02)%

(156)

(92)

(3)

(251)

(49)

(202)

2.06%

(11.43)%

(4)

1.52

(195)

(3.81)

Y-o-Y

15.3%

2.7%

(66.7)%

4.5%

(33.8)%

Q3-FY25

Q-o-Q

1,869

1,715

154

8.24%

2.94%

(5)

1.01

9.0%

7.0%

31.8%

172 bps

(86.0)%

2.2%

(19.0)%

26.8%

(75.0)%

14.1%

(23.6)%

(88) bps

(20.0)%

(24.0)%

50.5%

Annual Consolidated Financial Performance

Particulars (INR Mn)

Revenue from Operations

Total Expenses

EBITDA

EBITDA Margins (%)

Other Income

Depreciation

Finance Cost

PBT (Excl. Exceptional Items)

Exceptional Items

Share of Profit/(Loss) of Associates

PBT

Tax

PAT

PAT Margins (%)

Other Comprehensive Income

Total Comprehensive Income

Basic/Diluted EPS (INR)

Valiant Organics Limited | Q4-2025

FY25

7,188

6,651

537

7.47%

358

236

(7)

(34)

(0.47)%

(10)

(44)

(1.24)

FY24

7,231

6,849

382

5.28%

349

163

(37)

(34)

(16)

(87)

(3)

(84)

(1.16)%

(77)

(3.00)

Y-o-Y

(0.6)%

(2.9)%

40.6%

219 bps

(7.5)%

2.6%

44.8%

(56.3)%

(59.5)%

69 bps

(42.9)%

(58.7)%

Quarterly Standalone Financial Performance

Particulars (INR Mn)

Revenue from Operations

Total Expenses

EBITDA

EBITDA Margins (%)

Other Income

Depreciation

Finance Cost

PBT (Excl. Exceptional Items)

Exceptional Items

PBT

Tax

PAT

PAT Margins (%)

Other Comprehensive Income

Total Comprehensive Income

Basic/Diluted EPS (INR)

Valiant Organics Limited | Q4-2025

Q3-FY25

Q-o-Q

Q4-FY25

Q4-FY24

2,038

1,835

203

9.96%

1,768

1,786

(18)

(1.02)%

(156)

(50)

(106)

Y-o-Y

15.3%

2.7%

(66.7)%

4.5%

(33.8)%

1,869

1,715

154

8.24%

1.96%

(6.00)%

796 bps

2.46%

(5)

1.43

(99)

(3.80)

(4)

1.12

9.0%

7.0%

31.8%

172 bps

(86.0)%

2.2%

(19.0)%

26.8%

(13.0)%

(50) bps

25.0%

(16.7)%

27.7%

Annual Standalone Financial Performance

Particulars (INR Mn)

Revenue from Operations

Total Expenses

EBITDA

EBITDA Margins (%)

Other Income

Depreciation

Finance Cost

PBT (Excl. Exceptional Items)

Exceptional Items

PBT

Tax

PAT

PAT Margins (%)

Other Comprehensive Income

Total Comprehensive Income

Basic/Diluted EPS (INR)

Valiant Organics Limited | Q4-2025

FY25

7,188

6,651

537

7.47%

358

236

(30)

(0.42)%

(9)

(39)

(1.09)

FY24

6,772

6,376

396

5.85%

340

194

(109)

(51)

(21)

(30)

(0.44)%

(23)

(1.09)

Y-o-Y

6.1%

4.3%

35.6%

162 bps

5.3%

21.6%

2 bps

69.6%

HISTORICAL FINANCIAL OVERVIEW

Valiant Organics Limited | Q4-2025

Historical Consolidated Income Statement

Particulars (INR Mn)

Revenue from Operations

Total Expenses

EBITDA

EBITDA Margins (%)

Other Income

Depreciation

Finance Cost

PBT (Excl. Exceptional Items)

Exceptional Items

Share of Profit/(Loss) of Associates

PBT

Tax

PAT

PAT Margins (%)

Other Comprehensive Income

Total Comprehensive Income

Basic/Diluted EPS (INR)

Valiant Organics Limited | Q4-2025

FY22

11,533

9,484

2,049

17.77%

296

1,762

483

1,279

11.09%

1,285

40.51

FY23

10,518

8,875

1,643

15.62%

292

108

1,323

1,372

346

1,026

9.75%

1,027

31.50

FY24

7,231

6,849

382

5.28%

349

163

(37)

(34)

(16)

(87)

(3)

(84)

(1.16)%

(77)

(3.00)

FY25

7,188

6,651

537

7.47%

358

236

(7)

(34)

(0.47)%

(10)

(44)

(1.24)

Historical Consolidated Balance Sheet

Particulars (INR Mn)

FY23

FY24

FY25

Particulars (INR Mn)

EQUITY a) Equity Share Capital b) Other Equity c) Optionally Convertible Preference Shares d) Non Controlling Interest

LIABILITIES Non-Current Liabilities

Financial Liabilities a) Borrowings b) Lease Liabilities c) Other Financial Liabilities d) Provisions e) Deferred Tax Liabilities (Net) Current Liabilities

a) Financial Liabilities (i) Borrowings (ii) Trade Payables (iii) Other Financial Liabilities (iv) Lease Liabilities b) Other Current Liabilities c) Provisions

7,401 272 6,616 4 509

7,293 276 7,017 - -

7,253 280 6,973 - -

1,064

1,071

888

706 11

15 332 3,927

2,018 1,656 200 2 21 30

742 2 16 19 292 4,116

1,823 2,075 157 2 22 37

507 1 14 22 344 3,688

1,978 1,487 158 2 16 47

Non-Current Assets a) Property, Plant and Equipment c) Right-Of-Use Assets b) Capital Work In Progress d) Other Intangible Assets e) Goodwill on Consolidation f) Financial Assets (i) Investments (ii) Other Financial Assets g) Other Non-Current assets Current Assets a) Inventories b) Financial Assets (i) Investments (ii) Trade Receivables (iii) Cash and Cash Equivalents (iv) Other Bank balances (v) Loans (vi) Other financial assets

c) Other Current Assets d) Current Tax Assets (Net)

FY23

7,682 6,565 12 709 2 123

37 68 166 4,710 1,262

375 2,543 78 4 8 36 308 96

FY24

FY25

8,352 6,297 5 861 2 123

953 54 57 4,128 1,142

33 2,094 35 3 492 29 173 127

8,269 6,437 3 657 5 123

936 57 51 3,560 890

- 1,769 71 5 492 55 157 121

GRAND TOTAL - EQUITIES & LIABILITES

12,392

12,480

11,829

GRAND TOTAL – ASSETS

12,392

12,480

11,829

Valiant Organics Limited | Q4-2025

Historical Standalone Income Statement

Particulars (INR Mn)

Revenue from Operations

Total Expenses

EBITDA

EBITDA Margins (%)

Other Income

Depreciation

Finance Cost

PBT (Excl. Exceptional Items)

Exceptional Items

PBT

Tax

Profit After Tax

PAT Margins (%)

Other Comprehensive Income

Total Comprehensive Income

Diluted EPS (INR per share)

Valiant Organics Limited | Q4-2025

FY22

9,484

7,811

1,673

FY23

9,116

7,817

1,299

17.64%

14.25%

273

1,369

340

1,029

10.85%

1,037

36.81

276

105

947

996

240

756

8.29%

(11)

745

27.02

FY24

6,772

6,376

396

5.85%

340

194

(109)

(51)

(21)

(30)

(0.44)%

(23)

(1.09)

FY25

7,188

6,651

537

7.47%

358

236

(30)

(0.42)%

(9)

(39)

(1.09)

Historical Standalone Balance Sheet

Particulars (INR Mn) EQUITY

a) Equity Share Capital

b) Other Equity

FY23 6,661

272

6,385

c) Optionally Convertible Preference Shares

LIABILITIES

Non-Current Liabilities

Financial Liabilities

a) Borrowings

b) Lease Liabilities

c) Other Financial Liabilities

d) Provisions

e) Deferred Tax Liabilities (Net)

Current Liabilities

a) Financial Liabilities

(i) Borrowings

(ii) Trade Payables

(iii) Other Financial Liabilities

(iv) Lease Liabilities

b) Other Current Liabilities

c) Provisions

d) Current Tax Liabilities (Net)

932

589

326

3,465

1,602

1,643

179

FY24 6,649

276

6,373

1,071

742

292

3,703

1,410

2,075

157

FY25 6,616

280

6,336

888

507

344

3,289

1,607

1,460

156

Particulars (INR Mn) Non-Current Assets

a) Property, Plant and Equipment

b) Right-Of-Use Assets

c) Capital Work In Progress

d) Other Intangible Assets

e) Financial Assets

(i) Investments in Subsidiaries

(ii) Other Investments

(iii) Loans

f) Other Non-Current assets

Current Assets

a) Inventories

b) Financial Assets

(i) Investments

(ii) Trade Receivables

(iii) Cash and Cash Equivalents

(iv) Other Bank balances

(v) Loans

(vi) Other financial assets

c) Other Current Assets

d) Current Tax Assets (Net)

FY23 7,424

6,092

702

489

3,634

1,137

2,118

198

FY24 7,818

6,297

861

489

3,605

1,142

2,094

171

127

FY25 7,750

6,437

657

498

3,043

890

1,742

156

119

GRAND TOTAL - EQUITIES & LIABILITES

11,058

11,423

10,793

GRAND TOTAL – ASSETS

11,058

11,423

10,793

Consolidated Financial Highlights

Operational Revenue (INR Mn)

EBITDA (INR Mn) & EBITDA Margins (%)

PAT (INR Mn) & PAT Margins (%)

11,533

10,518

7,231

7,188

2,049

1,643

FY22

FY23

FY24

FY25

FY22

FY23

FY24

FY25

17.77%

15.62%

382

5.28%

537

7.47%

10,000

7,500

5,000

2,500

Net Debt to Equity (x)

0.64

0.32

0.33

Net Worth (INR Mn)

5,850

5,830

5,698

6,000

5,800

5,600

5,400

5,200

5,000

4,800

4,600

5,220

FY22

FY23

FY24

FY25

FY22

FY23

FY24

FY25

1,400

1,100

800

500

200

-100

-400

30.00%

25.00%

20.00%

15.00%

10.00%

5.00%

0.00%

-5.00%

1,279

1,026

11.09%

9.75%

FY22

FY23

-84

FY24

-34

FY25

-1.16%

-0.47%

Return on Capital Employed & Return on Equity (%)

26.31%

22.10%

ROCE

ROE (%)

17.56%

14.77%

1.26%

2.72%

FY22

FY23

-1.14%

FY24

-0.47%

FY25

Valiant Organics Limited | Q4-2025

Capital Market Information

Share Price up to 31st March, 2025

30%

10%

-10%

-30%

-50%

-70%

Apr-24

May-24

Jun-24

Jul-24

Aug-24

Sep-24

Oct-24

Nov-24

Dec-24

Jan-25

Feb-25

Mar-25

Price Data (As of 31st March, 2025)

Face Value

Market Price

52 Week H/L

Market Cap (Mn)

Equity Shares Outstanding (Mn)

1 Year Avg Trading Volume (‘000)

INR

10.0

260.3

455.2/225.0

7,288.2

28.0

68.6

Valiant Organics

Sensex

Shareholding pattern (As of 31st March, 2025)

FII; 0.37%

DII; 0.00%

Promoters; 37.91%

Public; 61.72%

Valiant Organics Limited | Q4-2025

Disclaimer

Valiant Organics Limited No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all events not current after the date of this presentation. Certain statements made in this presentation may not be based on historical information or facts and may be "forward looking statements" based on the currently held beliefs and assumptions of the management of Valiant Organics Limited (“Company”), which are expressed in good faith and in their opinion reasonable, including those relating to the Company’s general business plans and strategy, its future financial condition and growth prospects and future developments in its industry and its competitive and regulatory environment.

Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance or achievements of the Company or industry results to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements, including future changes or developments in the Company’s business, its competitive environment and political, economic, legal and social conditions. Further, past performance is not necessarily indicative of future results. Given these risks, uncertainties and other factors, viewers of this presentation are cautioned not to place undue reliance on these forward-looking statements. The Company disclaims any obligation to update these forward- looking statements to reflect future events or developments.

This presentation is for general information purposes only, without regard to any specific objectives, financial situations or informational needs of any particular person. This presentation does not constitute an offer or invitation to purchase or subscribe for any securities in any jurisdiction, including the United States. No part of it should form the basis of or be relied upon in connection with any investment decision or any contract or commitment to purchase or subscribe for any securities. None of our securities may be offered or sold in the United States, without registration under the U.S. Securities Act of 1933, as amended, or pursuant to an exemption from registration there from.

This presentation is confidential and may not be copied or disseminated, in whole or in part, and in any manner.

Valorem Advisors Disclaimer: Valorem Advisors is an Independent Investor Relations Management Service company. This Presentation has been prepared by Valorem Advisors based on information and data which the Company considers reliable, but Valorem Advisors and the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

Valorem Advisors also hereby certifies that the directors or employees of Valorem Advisors do not own any stock in personal or company capacity of the Company under review.

For further details please contact our Investor Relations Representatives: VALOREM ADVISORS Mr. Anuj Sonpal Tel: +91-22-49039500 Email: valiant@valoremadvisors.com

Valiant Organics Limited | Q4-2025

THANK YOU

Valiant Organics Limited | Q4-2025

← All Transcripts VALIANTORG Stock Page →

Valiant Organics Limited has informed the Exchange about Investor Presentation

Market Movers